The introduction of novel therapeutic approaches, such as gene-silencing RNA interference (RNAi) therapies and small molecule stabilizers, has revolutionized the management of transthyretin amyloidosis. These innovative treatments aim to inhibit the production of abnormal transthyretin protein or stabilize the native protein, thus preventing the formation of amyloid deposits and slowing disease progression. The expansion […]
